Epidemiological and clinical features of adult T‐cell leukemia–lymphoma in Japan, 2010–2011: A nationwide survey |
| |
Authors: | Kisato Nosaka Masako Iwanaga Yoshitaka Imaizumi Kenji Ishitsuka Kenichi Ishizawa Yoji Ishida Masahiro Amano Takashi Ishida Naokuni Uike Atae Utsunomiya Koichi Ohshima Kazuhiro Kawai Junji Tanaka Yoshiki Tokura Kensei Tobinai Toshiki Watanabe Kaoru Uchimaru Kunihiro Tsukasaki |
| |
Affiliation: | 1. Department of Hematology, Kumamoto University School of Medicine, Kumamoto, JapanThese authors contributed equally to this work;2. Department of Frontier Life Science, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JapanThese authors contributed equally to this work;3. Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan;4. Division of Hematology and Immunology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan;5. Department of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan;6. Department of Hematology and Oncology, Iwate Medical University, Iwate, Japan;7. Department of Dermatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan;8. Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;9. Department of Palliative Care, Saga‐ken Medical Center Koseikan, Saga, Japan;10. Department of Hematology, Imamura General Hospital, Kagoshima, Japan;11. Department of Pathology, Kurume University School of Medicine, Kurume, Japan;12. Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan;13. Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan;14. Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan;15. Department of Hematology, National Cancer Center Hospital, Tokyo, Japan;16. Department of Advanced Medical Innovation, St. Marianna University Graduate School of Medicine, Kawasaki, Japan;17. Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan;18. Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan;19. Department of Hematology, International Medical Center, Saitama Medical University, Saitama, JapanThese authors contributed equally to this work |
| |
Abstract: | Adult T‐cell leukemia–lymphoma (ATL) is a mature T‐cell malignancy associated with human T‐cell leukemia virus type 1 (HTLV‐1) infection. Japan is the most endemic country for HTLV‐1 and ATL in the world. Recent nationwide studies of Japanese blood donors reported that HTLV‐1 carriers spread from endemic areas to non‐endemic areas. Therefore, the latest information on nationwide epidemiological and clinical data for ATL is necessary to guide clinical practice. We undertook a multicenter, hospital‐based survey of newly diagnosed ATL patients from 2010 to 2011. A total of 996 patients with ATL were registered from 126 hospitals across Japan. Of those, 922 (487 men and 435 women) were included in the analysis. The median age at diagnosis was 68 years (interquartile range, 60–75 years). Overall, 67.2% of ATL was diagnosed in the Kyushu–Okinawa area. The most common subtype was acute (49.5%), followed by lymphoma (25.7%), chronic (14.2%), and smoldering (10.6%). Lymphoma type was more prevalent in men (60%), whereas chronic was more prevalent in women (60%). Half of patients with lymphoma type were aged over 70 years, whereas one‐third of patients with the chronic type were aged under 60 years. All of these characteristics were different from those of the previous nationwide surveys in the 1980s and 1990s. This survey clarified that half of current patients with ATL are aged over 68 years who were unable to receive intensive cytotoxic therapies. New less toxic agents for aged patients and further strategies to prevent the development of ATL from HTLV‐1 carrier status are needed. |
| |
Keywords: | Adult T‐cell leukemia– lymphoma
ATL
HTLV‐1 human T‐cell leukemia virus type 1 nationwide survey |
|
|